VTVT management to participate in September investor conferences
VTVT announced management will participate in September investor conferences. The company is advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.